ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 3023

Lipid Profile and Effect of Statin Treatment in Pooled Phase 2 and Phase 3 Baricitinib Studies

Iain B. McInnes1, Joel Kremer2, Paul Emery3, Steven H. Zuckerman4, Giacomo Ruotolo4, Chadi Saifan4, Lei Chen4, Shayami Thanabalasundrum4, Sarah Witt4 and William Macias4, 1Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, Great Britain, 2The Center for Rheumatology, Albany Medical College, Albany, NY, 3University of Leeds, Midlothian, United Kingdom, 4Eli Lilly and Company, Indianapolis, IN

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Lipids, Rheumatic disease, rheumatoid arthritis (RA) and statins, Rheumatology

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Session Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy III: Small Molecules and Early Intervention

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: In patients with active RA an increase in lipid analytes has been observed after treatment with janus kinase inhibitors and other disease-modifying antirheumatic drugs.1 The molecular mechanisms underlying these lipid changes are under active investigation.2

Methods: Data were analyzed from Phase 2 and Phase 3 studies of 4 mg oral baricitinib (bari) administered once daily in patients with moderately to severely active RA. The effect of statin therapy on lipid levels was evaluated in a subgroup of Phase 3 patients. In 1 Phase 3 study, the lipoprotein particle size and number were evaluated with nuclear magnetic resonance (NMR) at baseline and Week (Wk) 12.

Results: Treatment with bari was associated with increased levels of total cholesterol, triglycerides (TG), low‑density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL‑C) with a stable LDL‑C/HDL‑C ratio. The lipid elevation plateaued after Wk 12 (Table 1). By NMR, bari did not significantly affect total LDL particle number while the small, dense potentially more atherogenic LDL particle numbers decreased. Bari significantly increased HDL-C, the total number of HDL particles, all HDL subfractions, and TG-rich lipoproteins. The magnitude of lipid change from baseline was not significantly different between baseline statin users and nonusers (Table 2). In bari patients who initiated statin therapy before Wk 24 (N=18), the increased levels of total cholesterol and LDL-C decreased to baseline levels by Wk 24, while HDL-C levels remained elevated after statin therapy (Figure 1). Similar results in lipids changes and response to initiation of statin therapy were observed for apolipoprotein A1 and apolipoprotein B corresponding to HDL-C and LDL-C.

Conclusion: These analyses showed that bari was associated with increased LDL-C, HDL-C, and TG levels, with a stable LDL-C/HDL-C ratio. The magnitude of lipid change was not significantly different between baseline statin users and nonusers. In patients who initiated statin therapy during the study, the elevation in total cholesterol, LDL-C, and TG decreased to pretreatment levels in response to statin therapy, while HDL-C remained elevated with statin therapy. References:

  1. McGrath et al. Curr Rheumatol Rep. 2015.
  2. Robertson et al. Nat Rev Rheumatol. 2013.

   

.


Disclosure: I. B. McInnes, Eli Lilly and Company, AbbVie, Pfizer, Novartis, Roche, Janssen, 2,Eli Lilly and Company, AbbVie, Novartis, Pfizer, Roche, Janssen, 5; J. Kremer, Abbvie, Amgen, BMS, Genentech, GSK, Lilly, Novartis,Pfizer, 5,Abbvie, Genentech, Lilly, Novartis, Pfizer, 2,Genentech (non-promotional only, 8,Corrona, 1,Corrona, 3; P. Emery, Pfizer,MSD,Abbvie,BMS,UCB,Roche,Novartis,Samsung, Sandoz, Eli Lillyand Company, 5; S. H. Zuckerman, Eli Lilly and Company, 1,Eli Lilly and Company, 3; G. Ruotolo, Eli Lilly and Company, 1,Eli Lilly and Company, 3; C. Saifan, Eli Lilly and Company, 1,Eli Lilly and Company, 3; L. Chen, Eli Lilly and Company, 1,Eli Lilly and Company, 3; S. Thanabalasundrum, Eli Lilly and Company, 1,Eli Lilly and Company, 3; S. Witt, Eli Lilly and Company, 1,Eli Lilly and Company, 3; W. Macias, Eli Lilly and Company, 1,Eli Lilly and Company, 3.

To cite this abstract in AMA style:

McInnes IB, Kremer J, Emery P, Zuckerman SH, Ruotolo G, Saifan C, Chen L, Thanabalasundrum S, Witt S, Macias W. Lipid Profile and Effect of Statin Treatment in Pooled Phase 2 and Phase 3 Baricitinib Studies [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/lipid-profile-and-effect-of-statin-treatment-in-pooled-phase-2-and-phase-3-baricitinib-studies/. Accessed June 3, 2023.
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lipid-profile-and-effect-of-statin-treatment-in-pooled-phase-2-and-phase-3-baricitinib-studies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences